Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IPG 11406

Next Previous
X
Search
Drug Profile

IPG 11406

Alternative Names: IPG-11406

Latest Information Update: 04 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Immunophage Biotech
  • Class Anti-inflammatories; Antibodies; Antirheumatics; Small molecules
  • Mechanism of Action G protein-coupled receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Inflammatory bowel diseases; Multiple sclerosis; Rheumatoid arthritis; Systemic lupus erythematosus

Most Recent Events

  • 13 Feb 2024 Nanjing Immunophage Biotech plans a phase I trial for Inflammatory bowel diseases (In volunteers) in China in February 2024 (PO, Tablet) (NCT06255834)
  • 06 Feb 2024 Preclinical data released by Immunophage Biotech (Immunophage Biotech website, January 2024)
  • 05 Feb 2024 Phase I clinical trials in Inflammatory bowel diseases (In volunteers) in China (PO) as of February 2024 (Immunophage Biotech pipeline, February 2024) (NCT06255834)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top